Eqrx Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Eqrx Inc (EQRX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Eqrx Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Eqrx Inc | - | - | - | Yes |
| Competitors combined (183) | ||||
| High-Confidence Competitors (3) | - | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
EQRX Stock Performance relative to its Competitors
EQRX Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Gt Biopharma Inc | 282.9% | Outperformed |
| 2 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 3 | Gossamer Bio Inc | 282.9% | Outperformed |
| 4 | Spyre Therapeutics Inc | 282.9% | Outperformed |
| 5 | 180 Life Sciences Corp | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Eqrx Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Eqrx Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Eqrx Inc | 1,133.10 | - |
| Eli Lilly And Company | 1,138,091.20 | 79,665.80 |
| Akari Therapeutics Plc | 976,776.44 | - |
| Johnson and Johnson | 645,965.17 | 99,335.00 |
| Beone Medicines Ltd | 568,469.81 | 6,128.24 |
| Abbvie Inc | 505,868.44 | 64,386.00 |
| SUBTOTAL | 6,053,543.69 | 729,061.19 |
Sign in to see all competitors of Eqrx Inc .
Sources: Eqrx Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Eqrx Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Eqrx Inc's Competitors Named by the Company
Competitive relationships identified from Eqrx Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Springworks Therapeutics Inc | Company report | 85% |
| Silexion Therapeutics Corp | Company report | 85% |
| Elicio Therapeutics Inc | Company report | 85% |
| Black Diamond Therapeutics Inc | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Eqrx Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Eqrx Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Eqrx Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Eqrx Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Eqrx Inc | 1,133 | - | -1,038,492 |
| Eli Lilly And Company | 1,138,091 | 1,593,316 | 534,224 |
| Akari Therapeutics Plc | 976,776 | - | -4,674,667 |
| Johnson and Johnson | 645,965 | 705,504 | 114,311 |
| Beone Medicines Ltd | 568,470 | 510,686 | 54,642 |
| Abbvie Inc | 505,868 | 1,129,579 | 110,807 |
| PEERS TOTAL | 6,052,411 | 991,118 | 138,902 |
Eqrx Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 58.90 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Eqrx Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (456 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.2x | - |
| EV / EBITDA | - | 15.9x | - |
| P/B | 0.8x | 4.3x | -3.5x |
| Return on Equity | -20.27 % | industry aggregate | -31.73 % |
| Return on Invested Capital | -15.41 % | -4.07 % (avg) | -11.34 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Eqrx Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 31.7 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (38.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-38.7% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Eqrx Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Eqrx Inc | 6.08 | 22.62 | - |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Akari Therapeutics Plc | 0.23 | 0.26 | 0.04 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.16 | 0.75 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Eqrx Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Eqrx Inc | Q3 2023 | - | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| PEERS TOTAL | +11.1 % | -15.7 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Eqrx Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Eqrx Inc | Q3 2023 | - | - |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
Eqrx Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Eqrx Inc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Akari Therapeutics Plc | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 4.68% | 9.11% | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Eqrx Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Eqrx Inc | - | - |
| Eli Lilly And Company | 42.75 | 14.29 |
| Akari Therapeutics Plc | - | - |
| Johnson and Johnson | 39.91 | 6.50 |
| Beone Medicines Ltd | 858.25 | 92.76 |
| Abbvie Inc | 80.69 | 7.86 |
| PEERS AVERAGE | 59.40 | 8.30 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.